Deltex Medical Group PLC Two additional US platform programme accounts

TIDMDEMG

Deltex Medical Group PLC

18 January 2017

18 January 2017

Deltex Medical Group plc

("Deltex Medical", "Deltex" or "the Company")

Two additional US platform programme accounts: 30 platform accounts milestone passed

Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), is pleased to announce that it has added two new accounts to its platform programme in the USA.

Both new hospitals are in the North-East, one with 300 and the second with 400 beds. The hospitals expect to use 40 and 50 probes a month once they have completed their initial implementation programmes which are scheduled to start in January and February respectively.

The two new hospitals are the 29(th) and 30(th) US platform programme accounts and the 7(th) and 8(th) in the North-East territory. Deltex is recruiting an additional clinical trainer to support hospitals implementing ODM in this territory.

Ewan Phillips, Deltex Medical's Chief Executive, commented:

"Opening our 30(th) platform account in the USA is a key development in our US expansion plan as it gives us our planned critical mass of substantial hospital customers from which to expand going forward as well as generating returns from developing recurring, high margin revenues from supporting implementation of our products in these accounts."

For further information, please contact:-

 
 Deltex Medical Group            01243 774 837 
  plc                             [e-mail] 
 Nigel Keen, Chairman 
 Ewan Phillips, Chief 
  Executive 
 Jonathan Shaw, Group 
  Finance Director 
 
 Nominated Adviser & 
  Broker 
 Arden Partners plc              020 7614 5900 
 Chris Hardie 
 
   Financial Public Relations 
 IFC Advisory                    0203 053 8671 
 Tim Metcalfe 
  Graham Herring 
  Heather Armstrong 
 

Notes for Editors

Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's ODM is the only technology to measure continuously blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only company in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, ODM. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.

Company goal

ODM is increasingly recognised as a standard of care for patients undergoing major surgery and in critical care. The broader clinical area of haemodynamic management of which ODM is a core constituent is also now becoming widely accepted as an important major new medical modality. Consequently, the Company's focus is on maximising value from the opportunities presented as enhanced haemodynamic management is adopted into routine clinical practice around the world.

The Company is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.

There are over 3,200 monitors installed in hospitals around the world and around 700,000 patients have been treated to date using Deltex Medical's single patient disposable probes.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRASFLESWFWSEDF

(END) Dow Jones Newswires

January 18, 2017 02:00 ET (07:00 GMT)